The leading edge of Hetero Group, Hetero Biopharma, is steadily establishing itself as a path breaking Biosimilar developer. As a strong R&D driven company offering some of the blockbuster Biosimilar Drugs, we at Hetero Biopharma are bringing about a paradigm shift in the way patients suffering from various chronic conditions are treated.Read more >>>
With leadership in chemical therapeutics,
Hetero continues to lead from the front in the development and manufacturing of Biopharmaceuticals using novel technologies.
Genesis and Onwards
Conceptualized with the identification of Key Biosimilars
Completion of state-of-the-art R&D and Biologics manufacturing facility
Launch of Darbepoetin Alfa - First Biosimilar product of Hetero Biopharma
2nd Company in the world to launch Biosimilar Darbepoetin
Launch of Rituximab Injection - 2nd Biosimilar and 1st MAB of Hetero Biopharma
Expansion of the Biosimilar facility to cater the demands of Global markets
Launch of Bevacizumab Injection - our 3rd Biosimilar product
GMP accreditation by PIC/s member country
Entry in to global markets
Launch of Adalimumab Injection – our 4th Biosimilar product
Expansion of the new manufacturing block completed
Clinical evaluation of anti HER 2 mAb in progress
Progress in filing of biosimilars in regulated markets
1st company to launch Adalimumab autoinjector pen in India for better patient compliance
1st company in Africa to market Biosimilars with a dedicated team with a mission of REACHing every needy patient
Our Global Presence
Hetero Biopharma Insignia
The Hetero Biopharma Insignia is an apt interplay of a DNA and an hourglass. Together, they represent 'life' and 'time' thereby signifying Hetero's foray into modern biopharmaceuticals by not just offering high quality human biotechnology products but also focussing on their early commercialisation.
The colours Orange and Deep Yellow are obvious representation of the 'daybreak' and signify hope and life. The Grey colour signifies our intent to apply knowledge and expertise for better outcomes.